OOIR: Observatory of International Research

Papers

(The median citation count of Therapeutic Advances in Psychopharmacology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The role of Facebook groups in the management and raising of awareness of antidepressant withdrawal: is social media filling the void left by health services?	40
What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications	33
Clinical pharmacist interventions in elderly patients with mental disorders in primary care focused on psychotropics: a retrospective pre–post observational study	23
Clozapine discontinuation withdrawal symptoms in schizophrenia	21
Repetitive transcranial magnetic stimulation for major depressive disorder: basic principles and future directions	21
Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders	20
Current antipsychotic agent use and risk of venous thromboembolism and pulmonary embolism: a systematic review and meta-analysis of observational studies	20
Transcranial magnetic stimulation for post-traumatic stress disorder	19
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: a scoping review	17
The role of lumateperone in the treatment of schizophrenia	17
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review	16
Trends in benzodiazepine receptor agonists use and associated factors in the Belgian general older population: analysis of the Belgian health interview survey data	16
Cognitive effects of vortioxetine in older adults: a systematic review	15
Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review	14
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review	13
Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate	12
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study	12
Asenapine: an atypical antipsychotic with atypical formulations	12
Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review	12
Advances in pharmacotherapy for postpartum depression: a structured review of standard-of-care antidepressants and novel neuroactive steroid antidepressants	12
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action	12
Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey	11
Within-treatment changes in a novel addiction treatment program using traditional Amazonian medicine	11
History repeating: guidelines to address common problems in psychedelic science	10
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update	10

Liquorice for pain?	10
Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA	9
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry	8
Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication	8
Pathophysiology, prognosis and treatment of tardive dyskinesia	8
Classic psychedelics, health behavior, and physical health	8
Treatment strategies for clozapine-induced hypotension: a systematic review	7
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study	7
Identification of clinical phenotypes in schizophrenia: the role of lurasidone	7
Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital	7
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series	7
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies	7
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review	7
Synthetic opioids: a review and clinical update	7
The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: meta-analysis of randomized controlled trials	7
Will psilocybin lose its magic in the clinical setting?	7
Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study	6
Excess deaths in treatment-resistant depression	6
MTORC1 signaling as a biomarker in major depressive disorder and its pharmacological modulation by novel rapid-acting antidepressants	6
Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?	6
Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey	5
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine	5
Using a fingerstick test for haematological monitoring in patients treated with clozapine	5
Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial	5
Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression	5
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations	5
Outcomes of hyperbolic tapering of antidepressants	5
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study	4
Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital	4
Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report	4
Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder	4
Vortioxetine as adjunctive therapy in the treatment of schizophrenia	4
Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study	4
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia	4
Enduring neurological sequelae of benzodiazepine use: an Internet survey	4
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence	4
Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study	4
Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors	4
Brexanolone: panacea for postpartum depression? Reply to: ‘Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?’	3
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics	3
The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders	3
Clinical outcomes following switching antipsychotic treatment due to market withdrawal: a retrospective naturalistic cohort study of pipotiazine palmitate injection (Piportil Depot) discontinuation, s	3
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan	3
The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial	3
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis	3
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan	3
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation	3